AION Labs and BioMed X Launch Global AI Initiative for Drug Discovery

Mar 4, 2025
AION Labs, in partnership with BioMed X, has announced a global call for applications to develop AI-driven platforms for novel drug target combinations.

AION Labs, in collaboration with BioMed X, has announced in a press release the launch of a global call for applications aimed at forming a new startup focused on generative AI for novel target combinations. This initiative seeks to attract computational biologists, biomedical scientists, and AI experts to develop an AI-driven platform that identifies and validates molecular target combinations for multispecific biologic drugs.

The venture studio, based in Rehovot, Israel, and supported by pharmaceutical giants such as AstraZeneca, Merck, and Pfizer, aims to revolutionize drug discovery by moving beyond single-target approaches. The new platform will prioritize target combinations based on disease relevance and biomarker predictability, particularly in therapeutic areas like oncology and cardiovascular-kidney-metabolic diseases.

Interested candidates are invited to submit proposals through the BioMed X Career Space by May 5, 2025. The initiative underscores the potential of AI to transform biologic drug design by uncovering intricate molecular interactions and optimizing target combinations that traditional methods might overlook.

We hope you enjoyed this article

Consider subscribing to one of our newsletters like Life AI Weekly or Daily AI Brief.

Also, consider following us on social media:

Healthcare & Life Sciences AI AI Brief AI Brief (X)
Free newsletter

Life AI Weekly

Weekly coverage of AI applications in healthcare, drug development, biotechnology research, and genomics breakthroughs.

Guide
Specialist Ambient Medical Scribe Vendors

Specialist Ambient Medical Scribe Vendors

AI scribes that turn medical consultations into draft clinical notes

Whitepaper

Tensordyne Napier: What If One Rack Could Do the Work of Nine?

Tensordyne

This Tensordyne whitepaper presents Napier, an inference-focused AI processor and rack-scale system based on the company’s TDN Math logarithmic number system. It examines infrastructure requirements for large mixture-of-experts and agentic models, compares major inference architecture approaches, and details the TDN AIP processor, TDN72 pod, TDN Link fabric, and Napier Ultra configuration. The paper reports simulation-based performance, cost, and accuracy-validation results, including Tensordyne’s projected comparison of one Napier rack with a nine-rack Nvidia Rubin plus Groq deployment; the chip is reported as taped out and in fabrication.

Read more

You may also like

Free, six days a week

Daily AI Brief: the AI news that matters, in your inbox.